REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
3 hedge funds and large institutions have $15K invested in REGENERX BIOPHARMACEUTICALS in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
36% more capital invested
Capital invested by funds: $11K → $15K (+$4K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Capital Counsel
New York
|
+$7.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DDPIC
Deroy & Devereaux Private Investment Counsel
Bloomfield Hills,
Michigan
|
-$736 |
RGN Hedge Fund Activity: Q3 2013 in Review
3 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2013, worth a combined $15K — up 36% from $11K a quarter earlier.
Fund positioning in RGN was balanced in Q3 2013: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Capital Counsel, adding an estimated $7.27K. The largest seller was Deroy & Devereaux Private Investment Counsel, cutting an estimated $736.
- 3 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $15K of REGENERX BIOPHARMACEUTICALS stock for Q3 2013, up 36% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2013 and 0 closed out.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q3 2013 was Capital Counsel, an estimated $7.27K added.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q3 2013 was Deroy & Devereaux Private Investment Counsel, an estimated $736 sold.
Based on aggregated 13F filings for Q3 2013.